An Intrathecal CRISPR Strategy for Chronic Pain

Date: August 5, 2021

Time: 05:30PM - 06:30PM

You must be registered to participate!

Long-lasting Analgesia via Targeted In Situ Repression of NaV1.7

Recorded Aug. 5, 2021 @5:30pm Pacific


Genetic studies have identified in humans key targets pivotal to nociceptive processing. In particular, a hereditary loss-of-function mutation in NaV1.7, a sodium channel protein associated with signaling in nociceptive sensory afferents, leads to insensitivity to pain without other neurodevelopmental alterations.

We investigated targeted epigenetic repression of NaV1.7 in primary afferents via epigenome engineering approaches based on clustered regularly interspaced short palindromic repeats (CRISPR)–dCas9 and zinc finger proteins at the spinal level as a potential treatment for chronic pain.

This nonaccredited educational webinar is provided for information only.

  • Ana Moreno, PhD, Founder & CEO, Navega Therapeutics
  • Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company